ONE-TWENTY TWO: Trading Financial Markets
Exploring the poetry in financial markets for students of money and economy since the year 2000.
Intercept Pharmaceuticals, Inc. (ICPT) may indeed have the $5B blockbluster liver drug that RBC Capital Markets claimed in hiking its price target on the stock from $425 to $500. Gilead (GILD) may indeed buy out the company. Other analysts like Leerink Partners who raised its price target from $270 to $445, and Deutsche Bank who … Read more
At the time of writing, Windstream Holdings, Inc. (WIN) is surging 23.3% on news that the company received a favorable ruling from the IRS to convert to a REIT. From the press release: “Windstream (Nasdaq: WIN), a leading provider of advanced network communications, today announced plans to spin off certain telecommunications network assets into an … Read more
Just ahead of the start of the Apple Worldwide Developers Conference (WWDC), I wrote that I was preparing for a change in Apple’s trading patterns that would impact the Apple Trading Model (ATM). My main interest was in the coming 7-to-1 stock split and the potential for retail traders leaving options alone to trade directly … Read more
(This is an excerpt from an article I originally published on Seeking Alpha on January 26, 2014. Click here to read the entire piece.) It has been eight months since I exited my long position in Herbalife (HLF), but the story continues to fascinate me. This time around, bad news came in rapid sequence for … Read more
Solar City has traded down double digits after each of its three earnings reports: 3/6/2013 -14.4% 5/13/2013 -12.4% 8/7/2013 -10.8% So of course this will happen a fourth time in a row, right? Well, not so fast. The first post-earnings decline simply reversed a pre-earnings run-up. The stock continued upward from there. The second post-earnings … Read more